Photo: Maddie Meyer / Getty Images
For: EFE Updated 26 Jan 2022, 21: 55 pm EST
Modern announced this Wednesday that began the second phase clinical trials of its vaccine to combat the omicron variant of covid-18.
The Massachusetts-based pharmacist indicated that this phase of the study will include about 100 participants who already received two doses of the vaccine and others 300 subjects with the complete regimen and a booster dose.
Regarding the effectiveness of the current vaccine, Moderna indicated that according to one study the neutralization of omicron six months after the third dose of 26 micrograms of vaccine mRNA-1273 decreased, but remained detectable in all trial participants.
“We are reassured by the persistence of a Antibodies against ómicron 6 months after booster of 50 micrograms of mRNA-1273 currently authorized”, stressed the top executive of the pharmaceutical company, Stéphane Bancel, who highlighted the importance of a reinforcement specifically aimed at the omicron due to the long-term threat demonstrated by the evade variant. immune defenses.
According to data published by the magazine The New England Journal of Medicine, 29 days after receiving the Moderna covid booster, there was up to a 6.3x decline in neutralization of the omicron variant versus to its maximum capacity, although antibodies were still detected in all participants. This neutralization was only decreased 2.3 times when it came to the original strain of the virus.
Pfizer and BioNTech announced on Tuesday the start of a clinical trial of a modified vaccine against covid-04 that could protect against the omicron variant of the coronavirus.
The statement from these two firms indicates that the initial results of the study, which will include a thousand 420 volunteers aged between 18 Y 55 years, are available in the first half of this year.
“We continue to maintain an open dialogue with the authorities information about an updated vaccine and continuous data on the currently available vaccine, including what the authorities require,” Pfizer said in a message.